Lilly's New Diabetes Drug: 15% Weight Loss in 40 Weeks

For people living with diabetes, losing weight has always been frustratingly harder than it is for everyone else. A new drug from Eli Lilly might finally change that reality.

In a late-stage trial, diabetes patients taking retatrutide lost an average of 15.3% of their body weight over 40 weeks. That's nearly six times more than the placebo group, which lost just 2.6%.

The drug didn't just help with weight. Patients saw their HbA1C levels drop by 1.9 percentage points, a key measure of blood sugar control that doctors use to track diabetes management.

What makes this especially exciting is that the weight loss hadn't plateaued when the study ended. Kenneth Custer, who leads Lilly's cardiometabolic health unit, says this could be the highest weight loss ever recorded in a diabetes drug trial.

Retatrutide is what scientists call a "triple-G" drug because it targets three different hormone receptors at once. Think of it as hitting three helpful buttons in the body simultaneously, rather than just one.

The drug performed as well as Lilly's already popular diabetes medication Mounjaro when it came to blood sugar control. But the weight loss results stood out because diabetes patients typically face unique metabolic challenges that make shedding pounds particularly difficult.

Why This Inspires

Over 37 million Americans live with diabetes, and many struggle with weight management as part of their condition. For years, they've watched weight loss drugs work better for people without diabetes, creating an unfair disparity in treatment options.

This breakthrough suggests that gap might be closing. When medications can address both blood sugar and weight effectively, patients get relief from two interconnected health challenges at once.

The results also hint at a future where diabetes treatment isn't just about managing symptoms but actually helping people feel healthier overall. Weight loss can reduce strain on joints, improve sleep, boost energy, and lower risks for heart disease.

Retatrutide still needs FDA approval before reaching patients, but the trial results bring that possibility closer. Lilly designed this study specifically to show the drug works for people with diabetes, not just those seeking weight loss alone.

For millions watching their blood sugar and their weight every single day, this news offers something powerful: proof that better solutions are coming.